Spinraza

Blindness gene therapy price tag stirs controversyA patient advocacy group is criticizing the hefty price tag of a new treatment for blindness.
FDA green lights first treatment for rare spinal diseaseFDA approved nusinersen (Spinraza, Biogen), the first drug to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.